Inner Balance’s Oestra brings estradiol and progesterone together in a vaginal cream marketed for systemic hormone treatment. It is a distinctive product proposition. Evaluating it means asking about the complete formulation, not only whether its individual ingredients are familiar.
We reviewed the Oestra product and treatment pages in September 2026. This entry sets out the information a patient can request about evidence, dispensing and costs. It does not claim firsthand use, independent testing or proof that Oestra is equivalent to an approved hormone regimen.
In this entry
Begin with the intended treatment effect
The HRT page describes a compounded cream designed for vaginal administration and systemic effects. It should therefore not be grouped automatically with low-dose products intended mainly for local vaginal symptoms. The route is only one part of the prescription.
Ask which symptoms your clinician expects the treatment to address and why that approach fits your history. If you are comparing it with a patch and a separate capsule, ask how the two plans differ in evidence, flexibility and monitoring. Our route guide helps organize that conversation.
Separate three different evidence questions
First, there is evidence about a hormone class. Second, there is evidence about a particular approved product and its labeled use. Third, there is evidence about the compounded formulation being proposed to you. An answer to the first question does not automatically answer the other two.
Request studies relevant to the actual combination, concentration and route. Ask whether reported outcomes came from a controlled study or an internal review, how many people were followed and what unwanted effects were recorded. These questions do not assume a negative result; they identify what a marketing statement can and cannot establish.
Check approval status at the product level
The company identifies Oestra as compounded. The finished compounded preparation does not have FDA approval, even though approved medicines containing estradiol or progesterone exist. Facility oversight, pharmacy credentials and ingredient sourcing answer different questions from approval of the drug itself.
Read our FDA-approved versus compounded guide before the consultation. Ask what individual need justifies the proposed customization and whether an approved treatment could meet that need. A preference for a simpler routine is worth discussing, but it does not by itself prove superior safety or benefit.
Make uterine protection an explicit topic
For someone with a uterus who is considering systemic estrogen, the progestogen plan matters. Ask what evidence supports the progesterone amount and delivery method in the exact proposed prescription. The ingredient list alone cannot establish that the regimen provides adequate endometrial protection.
Ask how unexpected bleeding would be assessed and who arranges any local examination. Keep the treatment instructions available when contacting another clinician. Our progesterone notes explain the purpose of this discussion and why different preparations should not be substituted without clinical direction.
Confirm the pharmacy and the label
The reviewed Inner Balance pages contain differing references to 503A and 503B pharmacy arrangements. We could not identify the dispensing arrangement for an individual reader’s order from those statements. Ask for the actual pharmacy name, contact information and a clear label for the supplied product.
Use the prescription-reading checklist to record ingredients, strength, application instructions, storage and beyond-use information. If a pump or applicator is involved, ask how it should be used and what to do if it appears faulty. Obtain instructions from the pharmacist rather than improvising a dose.
Budget for the introductory period
The Oestra product page shows $199 per month for six months before a $99.50 monthly rate. Ask how the supplies and billing dates align. The price difference makes a single ongoing-rate headline a poor estimate for a new patient’s first months.
Also ask about the cost of dose adjustments and the conditions attached to any refund promise. Put the amount actually payable over 90 days into the cost worksheet, keeping any additional charge separate. Financial guarantees should never be understood as guarantees that medication has no side effects.
Decide what remains unresolved
The product’s convenience claim is understandable: some people would prefer one routine to several. The unresolved questions concern the evidence for the specific prescription, its clinical rationale, dispensing details and follow-up. Those are matters to settle with the prescriber before choosing it.
Compare Winona for another compounded offering and Pandia Health for approved medicine choices. Alloy provides a patch-based comparison. None of these reviews replaces an assessment of what route, dose and combination are appropriate for you.
CHECK THE ORIGINAL
The source record
Provider pages document their own offers. Medical and regulatory sources provide treatment context. This is not a record of personal patient testing. All sources checked September 20, 2026.